It recruits an E3 ligase to induce highly selective (>1000‐fold) degradation of SMARCA2 and demonstrates anti‐proliferative activity against SMARCA4‐deficient tumours in vitro and in vivo with good tolerability.213. The gene discussed is SMARCA2; the disease is neoplasm.